ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1351

Mortality and Prognostic Factors of Pneumocystis Pneumonia in Patients with Connective Tissue Diseases

Mitsuhiro Akiyama1, Yuko Kaneko2 and Tsutomu Takeuchi2, 1Division of Rheumatology, Department of Internal Medicine,, Keio University School of Medicine, Tokyo, Japan, 2Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Co-morbidities, Connective tissue diseases, Infection, outcomes and prognostic factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: Miscellaneous Rheumatic and Inflammatory Diseases - Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:  Pneumocystis pneumonia (PCP) is one of the severe opportunistic infections in immunocompromised patients. PCP is still a leading cause of death in patients with connective tissue diseases treated with glucocorticoid, immunosuppressant and biologic agents. However, the mortality rate and factors related to death for PCP remain unclear. The aim of this study is to identify the prognostic factors for PCP in immunosuppressed patients with connective tissue diseases.

Methods:  A total of 52 patients with connective tissue diseases developing PCP were included in this study. PCP was diagnosed by clinical symptoms, radiological findings, respiratory specimens (the microscopic demonstration of Pneumocystis jirovecii or pneumocystis-specific nested polymerase chain reaction) and serum β-D glucan. The patients were divided into two groups according to the outcome (Survivors group or Non-survivors group). Baseline demographics, treatment for the underlying connective tissue disease, laboratory findings at the diagnosis of PCP, and treatment for PCP were compared between the two groups.

Results:   Of 52 patients with PCP, 6 deceased and a mortality rate was 11.5%. There were no significant differences in age, gender, type of connective tissue disease, previous immunosuppressive treatments between survivors and non-survivors. The treatment regimen for PCP was not different between the two groups. The initial trimethoprim-sulfamethoxazole treatment failure was also not statistically different between the two groups. In univariate analysis, while the levels of serum β-D glucan, KL-6, IgG and PaO2, and the number of lymphocytes were not statistically different, the lower level of serum albumin, and higher levels of serum C-reactive protein and lactate dehydrogenase were significantly associated with mortality. Multivariate analysis showed that the lower level of serum albumin was an independent poor prognostic factor for the death with PCP.

Conclusion:  The low serum albumin is an independent prognostic factor for mortality in PCP developed in immunosuppressed patients with connective tissue diseases.


Disclosure: M. Akiyama, None; Y. Kaneko, None; T. Takeuchi, None.

To cite this abstract in AMA style:

Akiyama M, Kaneko Y, Takeuchi T. Mortality and Prognostic Factors of Pneumocystis Pneumonia in Patients with Connective Tissue Diseases [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/mortality-and-prognostic-factors-of-pneumocystis-pneumonia-in-patients-with-connective-tissue-diseases/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mortality-and-prognostic-factors-of-pneumocystis-pneumonia-in-patients-with-connective-tissue-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology